Video
Dr. Ramaprasad Srinivasan highlights the latest treatment advances in kidney cancer
Author(s):
The comprehensive review includes key developments in both clear cell and non-clear cell histology.
Video Player is loading.
Ramaprasad Srinivasan, MD, PhD, Urologic Oncology Branch, National Cancer Institute, summarizes the latest advances in the treatment paradigm for patients with renal cell carcinoma (RCC).
At the 2020 Society of Urologic Oncology Annual Meeting, Srinivasan shared data on one of these advances: a phase 2 study in which the investigational HIF-2α inhibitor MK-6482 showed durable efficacy in patients with Von Hippel-Lindau–associated RCC and non-renal lesions.
In this video, Srinivasan provides a comprehensive review the latest breakthroughs in all areas of RCC, including both clear cell and non-clear cell histology.
Related Videos
Study data point to gender disparities in oncology research citations
Nitin Yerram, MD, highlights new resource center for patients with renal cell carcinoma
Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025
Darren Feldman, MD, on study of 177Lu-girentuximab plus nivolumab for ccRCC
Francesca Jackson-Spence, MBChB, details the ongoing SAMETA trial in papillary renal cancer
Kate Gessner, MD, on systemic agents vs MDT after kidney cancer progression
Taylor Goodstein, MD, highlights project on staging in larger kidney tumors
Chad Tang, MD: Considerations for SBRT in metastatic RCC
Considering patient-reported outcomes in kidney cancer care, with Nicholas Zaorsky, MD, PhD
Nicholas Zaorsky, MD, MS: Protecting kidney function after local renal cell carcinoma therapy
Related Content
